{"id":"https://openalex.org/W1994702154","doi":"https://doi.org/10.1016/0014-2999(84)90460-6","title":"Anxiolytic-like properties of fominoben","display_name":"Anxiolytic-like properties of fominoben","publication_year":1984,"publication_date":"1984-01-01","ids":{"openalex":"https://openalex.org/W1994702154","doi":"https://doi.org/10.1016/0014-2999(84)90460-6","mag":"1994702154","pmid":"https://pubmed.ncbi.nlm.nih.gov/6142823"},"language":"en","primary_location":{"id":"doi:10.1016/0014-2999(84)90460-6","doi":"https://doi.org/10.1016/0014-2999(84)90460-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(84)90460-6","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063501456","display_name":"Jacqueline N. Crawley","orcid":"https://orcid.org/0000-0002-1224-995X","observed_orcids":["https://orcid.org/0000-0002-1224-995X"]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline N. Crawley","raw_affiliation_strings":["Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071978636","display_name":"Lisa K. Blumstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa K. Blumstein","raw_affiliation_strings":["Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004338485","display_name":"Frank Baldino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Baldino","raw_affiliation_strings":["Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Central Research and Development Department, E.I. DuPont de Nemours and Company, Glenolden, PA 19036, USA","institution_ids":["https://openalex.org/I1316910977"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1316910977"],"apc_list":{"value":3230,"currency":"USD","value_usd":3230},"apc_paid":null,"fwci":0.8212,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.63952835,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"97","issue":"3-4","first_page":"277","last_page":"281"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.8403000235557556,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.8403000235557556,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.06120000034570694,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13047","display_name":"Pharmacological Receptor Mechanisms and Effects","score":0.020500000566244125,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.9079999923706055},{"id":"https://openalex.org/keywords/benzodiazepine-receptor","display_name":"benzodiazepine receptor","score":0.9160000085830688},{"id":"https://openalex.org/keywords/ro-15-1788","display_name":"Ro 15-1788","score":0.8859999775886536},{"id":"https://openalex.org/keywords/antitussives","display_name":"antitussive agents","score":0.7509999871253967},{"id":"https://openalex.org/keywords/exploratory-behavior","display_name":"exploratory behavior","score":0.6779999732971191},{"id":"https://openalex.org/keywords/diazepam","display_name":"diazepam","score":0.7749999761581421},{"id":"https://openalex.org/keywords/pentylenetetrazole-induced-seizures","display_name":"pentylenetetrazole-induced seizures","score":0.7870000004768372},{"id":"https://openalex.org/keywords/benzodiazepine-binding-site","display_name":"benzodiazepine binding site","score":0.7319999933242798}],"concepts":[{"id":"https://openalex.org/C2778173252","wikidata":"https://www.wikidata.org/wiki/Q83871","display_name":"Benzodiazepine","level":3,"score":0.7755287885665894},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.7455253601074219},{"id":"https://openalex.org/C2776819090","wikidata":"https://www.wikidata.org/wiki/Q412391","display_name":"Pentylenetetrazol","level":4,"score":0.7448577880859375},{"id":"https://openalex.org/C2776175493","wikidata":"https://www.wikidata.org/wiki/Q210402","display_name":"Diazepam","level":2,"score":0.657632052898407},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6143876910209656},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6024362444877625},{"id":"https://openalex.org/C2778409475","wikidata":"https://www.wikidata.org/wiki/Q421920","display_name":"Flumazenil","level":4,"score":0.587765634059906},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4751175045967102},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4106734097003937},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.33330589532852173},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.23145028948783875},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.20647993683815002},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.18434181809425354},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1018134355545044},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.10135284066200256}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D001570","descriptor_name":"Benzodiazepinones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003975","descriptor_name":"Diazepam","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005442","descriptor_name":"Flumazenil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0014-2999(84)90460-6","doi":"https://doi.org/10.1016/0014-2999(84)90460-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(84)90460-6","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:6142823","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6142823","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W168945570","https://openalex.org/W1966385194","https://openalex.org/W1978342290","https://openalex.org/W1992982415","https://openalex.org/W2002312324","https://openalex.org/W2008444968","https://openalex.org/W2011913779","https://openalex.org/W2013082402","https://openalex.org/W2017363078","https://openalex.org/W2017659544","https://openalex.org/W2022356586","https://openalex.org/W2030804523","https://openalex.org/W2042554229","https://openalex.org/W2043598410","https://openalex.org/W2059354993","https://openalex.org/W2061163632","https://openalex.org/W2074764238","https://openalex.org/W2075672970","https://openalex.org/W4252196055"],"related_works":["https://openalex.org/W2086568057","https://openalex.org/W1992982415","https://openalex.org/W2048990934","https://openalex.org/W2460134272","https://openalex.org/W2000573895","https://openalex.org/W2046447636","https://openalex.org/W101372224","https://openalex.org/W2032142851","https://openalex.org/W2061376460","https://openalex.org/W1988151569"],"abstract_inverted_index":null,"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}